Coffee? You might as well be commuting by buggy. Old-school stimulants like caffeine, amphetamines and the drug Ritalin are about to be marginalized by eugeroics. This emerging breed of "wakefulness" pills promises to keep the workers of tomorrow not just awake, but alert, on-task and feeling fine through the night and well into the next day. Remember these names, because they´re your future: Modafinil, approved by the Food and Drug Administration in 1998 for the treatment of narcolepsy and marketed in the U.S. as Provigil, is already giving a competitive edge to everyone from Air Force pilots on 40-hour missions to (less legally) college students cramming for exams. The drug´s maker, Cephalon in Frazer, Pennsylvania, is awaiting FDA approval for armodafinil, which promises even longer periods of wakefulness on a single dose, and Irvine, California based Cortex is working on its own drug, code-named CX717 and developed with funding from the military. The drugs are targeted at sleep disorders like narcolepsy, but it´s their dramatic potential influence on the workplace that has researchers and efficiency experts buzzing.